Aim immunotech outlines recent significant progress across clinical development pipeline and provides update on positive pre-clinical and ip developments
Company's priority oncology clinical programs continue to advance toward key milestones additional clinical trial site now open at university of nebraska for phase 2 study of ampligen® for the treatment of pancreatic cancer (amp-270) ongoing progress toward phase 1 data in clinical development program of ampligen for the treatment of early-stage triple negative breast cancer significant findings from a new analysis support the potential to identify patients with lapc that could respond better to ampligen company bolsters patent portfolio for ampligen as a potential therapy against ebola virus disease ocala, fla., june 12, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today provided an update on its ongoing clinical development programs evaluating ampligen® (rintatolimod), a dsrna and highly selective tlr3 agonist immune-modulator with broad spectrum activity.
AIM Ratings Summary
AIM Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission